Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Tester tillegget av anti-kreft viral terapi Telomelysin™ til kjemoradiasjon for pasienter med avansert esophageal cancer og ikke er kandidater for kirurgi

9. september 2026 oppdatert av: NRG Oncology

Fase I-studie med ekspansjonskohort av OBP-301 (Telomelysin™) og endelig kjemoradiasjon for pasienter med lokalt avansert esophageal og gastroøsofageal kreft som ikke er kandidater for kirurgi

This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Detaljert beskrivelse

PRIMARY OBJECTIVE:

I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.

SECONDARY OBJECTIVES:

I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.

II. To assess the number of clinical complete responses (cCR).

III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.

EXPLORATORY OBJECTIVE:

I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.

OUTLINE:

This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.

Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.

Studietype

Intervensjonell

Registrering (Faktiske)

16

Fase

  • Fase 1

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • California
      • Duarte, California, Forente stater, 91010
        • City of Hope Comprehensive Cancer Center
      • South Pasadena, California, Forente stater, 91030
        • City of Hope South Pasadena
      • Upland, California, Forente stater, 91786
        • City of Hope Upland
    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Moffitt Cancer Center
    • Kansas
      • Fairway, Kansas, Forente stater, 66205
        • University of Kansas Clinical Research Center
      • Kansas City, Kansas, Forente stater, 66160
        • University of Kansas Cancer Center
      • Westwood, Kansas, Forente stater, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital Cancer Center
    • New Jersey
      • Basking Ridge, New Jersey, Forente stater, 07920
        • Memorial Sloan Kettering Basking Ridge
      • Middletown, New Jersey, Forente stater, 07748
        • Memorial Sloan Kettering Monmouth
      • Montvale, New Jersey, Forente stater, 07645
        • Memorial Sloan Kettering Bergen
    • New York
      • Commack, New York, Forente stater, 11725
        • Memorial Sloan Kettering Commack
      • Harrison, New York, Forente stater, 10604
        • Memorial Sloan Kettering Westchester
      • New York, New York, Forente stater, 10065
        • Memorial Sloan Kettering Cancer Center
      • Uniondale, New York, Forente stater, 11553
        • Memorial Sloan Kettering Nassau
    • Ohio
      • Columbus, Ohio, Forente stater, 43210
        • Ohio State University Comprehensive Cancer Center
    • Texas
      • Houston, Texas, Forente stater, 77030
        • UT MD Anderson Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration

    • Gastroesophageal junction tumors must be Siewert type I/II
  • Required diagnostic workup for study entry:

    • History/physical examination prior to registration
    • Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
    • Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
    • Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
    • Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration

  • Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)

  • Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)

  • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)

  • AST/ALT ≤ 2.5 x ULN

  • Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;

  • Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures

  • Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months

  • Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device

  • The patient must provide study-specific informed consent prior to study entry

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)

    • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
    • For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease including:

    • Positive malignant cytology of the pleura, pericardium or peritoneum
    • Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
    • Tracheoesophageal fistula
    • Radiographic evidence of distant organ involvement
    • Non-regional lymph nodes that cannot be contained within a radiation field
  • More than 1 esophageal lesion

  • Prior systemic chemotherapy for the study cancer

  • Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields

  • Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis

  • For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse

  • Uncontrolled diabetes

  • Infection requiring IV antibiotics at the time of registration

  • Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry

  • Received live vaccine within 30 days prior to registration

  • Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab

  • Breast feeding females

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Treatment (OBP-301, carboplatin, paclitaxel, radiation)

Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.

Intravenously (IV)

Andre navn:
  • Blastokarb
  • Carboplat
  • Carboplatin Hexal
  • Carboplatino
  • Karboplatina
  • Karbosin
  • Karbosol
  • Carbotec
  • CBDCA
  • Displata
  • Ercar
  • JM-8
  • Nealorin
  • Novoplatinum
  • Paraplatin
  • Paraplatin AQ
  • Platinwas
  • Ribocarbo

Intravenously (IV)

Andre navn:
  • Taxol
  • Anzatax
  • Asotax
  • Bristaxol
  • Praxel
  • Taxol Konzentrat

Daily fractions

Andre navn:
  • Kreft Strålebehandling
  • Bestråle
  • Bestrålt
  • Bestråling
  • Stråling
  • Stråleterapi, NOS
  • Radioterapeutika
  • RT
  • Terapi, stråling
  • RADIOTERAPI

Intra-tumoral injection

Andre navn:
  • OBP-301
  • Telomelysin™

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
Tidsramme: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:

  • Any grade ≥3 adverse event EXCEPT for the following:

    • Grade 3 nausea/vomiting
    • Grade 3 esophagitis or dehydration
    • The first occurrence of grade 3/4 neutropenia
    • Grade 3/4 lymphopenia (since this is a known toxicity of chemoradiation and OBP-301)
  • Any toxicity that leads to a >14-day cumulative delay in chemoradiation.

If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL).

From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere i live etter 1 og 2 år
Tidsramme: Etter 1 og 2 år
Etter 1 og 2 år
Number of Participants by Highest Grade Adverse Event Reported
Tidsramme: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.

The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data.

From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
Number of Participants With Clinical Complete Response (cCR)
Tidsramme: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.

Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:

  • Complete case analysis only includes eligible participants who started protocol treatment and were assessed for cCR;
  • Sensitivity analysis includes all eligible participants who started protocol treatment and counts participants without an assessment as not achieving a cCR.
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
Number of Participants Alive Without Progression at 1 and 2 Years
Tidsramme: At 1 and 2 years

Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease.

At 1 and 2 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Geoffrey Y Ku, NRG Oncology

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

2. desember 2021

Primær fullføring (Faktiske)

6. oktober 2024

Studiet fullført (Antatt)

6. oktober 2029

Datoer for studieregistrering

Først innsendt

12. mai 2020

Først innsendt som oppfylte QC-kriteriene

12. mai 2020

Først lagt ut (Faktiske)

18. mai 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Andre studie-ID-numre

  • NRG-GI007
  • U10CA180868 (U.S. NIH-stipend/kontrakt)
  • NRG-GI007 (Annen identifikator: CTEP)
  • NCI-2020-02320 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
  • NRG-GI007 (Annen identifikator: NRG Oncology)

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere